Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, is set to present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026, at 3:50 p.m. Eastern Time. The company's President and CEO, Shawn Singh, will provide a corporate overview outlining their innovative approach to neuroscience through nose-to-brain neurocircuitry. Following the presentation, a replay of the webcast will be accessible on the “Events” page in the “Investors” section of Vistagen’s website.

Vistagen specializes in developing a novel class of intranasal product candidates known as pherines. These products aim to harness the brain's neurocircuitry for therapeutic purposes without the need for systemic absorption into the bloodstream, potentially offering a safer alternative to traditional medications. The company's pipeline features five investigational product candidates targeting significant mental health and menopausal conditions. Notably, Vistagen's pherines are focusing on areas with high unmet needs, including social anxiety disorder, major depressive disorder, and vasomotor symptoms associated with menopause, such as hot flashes.

As Vistagen continues to advance its research and development efforts, its innovative approach could redefine treatment options in neuroscience and improve the overall quality of care for patients facing these prevalent health issues. Investors and interested parties can keep abreast of Vistagen’s developments and updates through their website and by reaching out to their investor and media relations contacts.

For more information, visit Vistagen at www.Vistagen.com, and stay tuned for insights from their presentation at the upcoming conference.

As Vistagen (Nasdaq: VTGN) gears up to participate in the 46th Annual TD Cowen Healthcare Conference, investors should be keenly aware of the unique market position Vistagen occupies within the biopharmaceutical sector. The company is pioneering the development of intranasal product candidates, termed pherines, which leverage nose-to-brain neurocircuitry. This innovative delivery method aims to provide therapeutic benefits rapidly, offering a potential alternative to traditional pharmacological treatments, especially for conditions such as social anxiety disorder and major depressive disorder.

As the healthcare landscape evolves, Vistagen's focus on a safer, non-invasive approach may resonate positively with both patients and healthcare providers emphasizing safety and efficacy. Their current pipeline is robust, featuring five investigational compounds targeting prevalent conditions, which places Vistagen in a strategically advantageous position to meet high unmet medical needs.

However, investors should remain cautious. The transition from clinical trials to commercial viability is fraught with potential pitfalls, including regulatory approval, market acceptance, and competitive dynamics in the mental health and menopause sectors. While the innovative aspects of the pherines suggest considerable market potential, Vistagen's financial health, including cash reserves and burn rate, warrants scrutiny.

Investors should consider the company's valuation in light of upcoming data releases and announcements that may emerge from the conference. Key performance metrics, clinical trial progress, or collaborations could move the stock significantly. Additionally, earnings reports and broader market trends in biotech could impact Vistagen’s share price.

In conclusion, while Vistagen presents a compelling investment opportunity due to its unique product candidates and focus on significant unmet medical needs, investors should adopt a balanced approach, weighing potential rewards against the inherent risks of clinical-stage biopharmaceutical investments.